Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/18686
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGianatti, Emily J-
dc.contributor.authorHoermann, Rudolf-
dc.contributor.authorLam, Que T-
dc.contributor.authorDupuis, Philippe-
dc.contributor.authorZajac, Jeffrey D-
dc.contributor.authorGrossmann, Mathis-
dc.date2015-07-23-
dc.date.accessioned2018-08-30T06:44:23Z-
dc.date.available2018-08-30T06:44:23Z-
dc.date.issued2016-01-
dc.identifier.citationClinical endocrinology 2016; 84(1): 55-62-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/18686-
dc.description.abstractTo assess the effect of testosterone treatment on cardiac biomarkers in men with type 2 diabetes (T2D). Randomized double-blind, parallel, placebo-controlled trial. Men aged 35-70 years with T2D and a total testosterone level ≤12·0 nmol/l (346 ng/dl) at high risk of cardiovascular events, median 10-year United Kingdom Prospective Diabetes Study (UKPDS) coronary heart disease (CHD) risk 21% (IQR 16%, 27%). Eighty-eight participants were randomly assigned to 40 weeks of intramuscular testosterone undecanoate (n = 45) or matching placebo (n = 43). N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT). Testosterone treatment reduced NT-proBNP (mean adjusted difference (MAD) in change over 40 weeks across the testosterone and placebo groups, -17·9 ng/l [95% CI -32·4, -3·5], P = 0·047), but did not change hs-cTnT (MAD, 0·41 ng/l (95% CI -0·56, 1·39), P = 0·62). Six men, three in each group experienced an adverse cardiac event, displaying already higher baseline NT-proBNP (P < 0·01) and hs-cTnT levels (P = 0·01). At baseline, 10-year UKPDS CHD risk was associated positively with NT-proBNP (τ = 0·21, P = 0·004) and hs-cTnT (τ = 0·23, P = 0·003) and inversely with testosterone (total testosterone τ = -0·18, P = 0·02, calculated free testosterone τ = -0·19, P = 0·01), but there was no significant association between testosterone and cardiac biomarkers (P > 0·05). In this trial of men with T2D and high cardiovascular risk, testosterone treatment reduced NT-proBNP and did not change hs-cTnT. Further studies should determine whether men with increased cardiac biomarkers prior to testosterone therapy are at higher risk of testosterone treatment-associated adverse cardiac events.-
dc.language.isoeng-
dc.titleEffect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes.-
dc.typeJournal Article-
dc.typeRandomized Controlled Trial-
dc.typeResearch Support, Non-U.S. Gov't-
dc.identifier.journaltitleClinical endocrinology-
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Biochemistry, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia-
dc.identifier.affiliationEndocrine Unit, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1111/cen.12842-
dc.identifier.orcid0000-0001-8261-3457-
dc.identifier.pubmedid26120052-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.